Dupilumab Improves Disease Control and Patient-Reported Outcomes in Adults with Atopic Dermatitis in Clinical Practice: Subgroup Analysis of Black/African American Population from RELIEVE-AD

Main Article Content

Raj Chovatiya
Jingdong Chao
Chien-Chia Chuang
Min Yang
Brad Shumel
Bruno Martins
Gaelle Bégo-Le-Bagousse
Debra Sierka
Dimittri Delevry


atopic dermatitis, dupilumab, disease control, skin symptoms, sleep problems, ADCT


1. Wittkowski A, et al. Psychol Health Med 2007;12(4):433-444.

2. Dupixent® (dupilumab). Highlights of prescribing information. https://www.regeneron.com/downloads/dupixent_fpi.pdf. Accessed August 8, 2023.

3. Dupixent® (dupilumab). Summary of product characteristics. https://www.ema.europa.eu/en/documents/productinformation/dupixent-epar-product-information_en.pdf. Accessed August 8, 2023.

4. Simpson EL, et al. N Eng J Med 2016;375(24):2335-2348.

5. Simpson EL. Dermatol Ther (Heidelb) 2017;7(2):243-248.

6. Deleuran M, et al. J Am Acad Dermatol 2020;82(2):377-388.

7. Simpson EL, et al. JAMA Dermatol 2020;156(1):44-56.

8. Cork MJ, et al. Br J Dermatol 2020;182(1):85-96.

9. Paller AS, et al. J Am Acad Dermatol 2020;83(5):1282-1293.

10. Cork MJ, et al. Br J Dermatol 2021;184(5):857-870.

11. Paller AS, et al. Lancet 2022;400(10356):908-919.

12. Blauvelt A, et al. Am J Clin Dermatol 2022;23(3):365-383.

13. Strober B, et al. JAMA Dermatol 2022;158(2):142-150.

Most read articles by the same author(s)

1 2 > >>